{'fraction_non_alphanumeric': 0.02135774218154081, 'fraction_numerical': 0.007627765064836003, 'mean_word_length': 5.368932038834951, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Evolving Treatment Strategies for Anaemia in Cancer: Experience with Epoetin Beta

Epoetin represents the standard of care in the management of cancer therapy-related anaemia, increasing haemoglobin levels, reducing transfusion need and improving patient quality of life (QoL). Recent research aimed at improving convenience and ease of use has involved all epoetins. In particular, it has confirmed that epoetin beta 30,000 IU once weekly is equally effective as the conventional 10,000 IU three-times weekly regimen in alleviating cancer-related anaemia. Ongoing research aimed at improving still further the effectiveness of epoetins in anaemia treatment is examining the role of concomitant intravenous iron during epoetin beta therapy. With the recent debate over whether epoetin therapy has an effect on treatment outcome and survival, well-designed trials specifically powered to assess survival are required. The BReast cancer – Anaemia and the Value of Erythropoietin (BRAVE) trial is such a study, assessing the impact of epoetin beta on survival and QoL of patients with metastatic breast cancer scheduled to receive anthracycline- and/or taxane-based chemotherapy. The findings of such studies are expected to lead to a greater understanding of the optimal use of epoetins in cancer-related anaemia.